{
  "docId": "019de075-e64c-773b-a5bd-08e51f7033a7",
  "docSlug": "8122e3ca3ef658190e4851ff70e19f61",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 25 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 17,
  "pageCount": 25,
  "prevPage": 16,
  "nextPage": 18,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e64c-773b-a5bd-08e51f7033a7/17",
  "deckHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7",
  "deckJsonHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7.json",
  "deckAnchorHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7#slide-17",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.23,
        "x": 0.024,
        "y": 0.294
      },
      "kind": "list",
      "text": "Imdusiran provided robust and comparable HBsAg declines regardless of dose, dosing interval, HBeAg or DNA status",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7c4684c1-befa-48b6-a0dd-0d4168f00a06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.23,
        "x": 0.528,
        "y": 0.294
      },
      "kind": "list",
      "text": "Imdusiran results in HBV-specific T-cell immune restoration and decrease of exhausted T-cells in some patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84eee6b9-1c13-4e0f-b6eb-eeb6029a655c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.23,
        "x": 0.78,
        "y": 0.294
      },
      "kind": "list",
      "text": "Imdusiran was generally safe and well-tolerated after completing dosing in 41 patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c62c84a-aeeb-4c65-93da-317bd5f73797",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.23,
        "x": 0.276,
        "y": 0.294
      },
      "kind": "list",
      "text": "Discontinuation of both imdusiran and NA-therapy results in sustained reduction in HBsAg and HBV DNA in 7 of 9 patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5d3e9fa-c255-4e54-b536-d29ea2e05561",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.55,
        "x": 0.076,
        "y": 0.065
      },
      "kind": "title",
      "text": "AB-729-001 Clinical Trial Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25084250-b7c5-49cb-89f1-fc4231a2eebd",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}